Equities analysts expect that Alimera Sciences Inc (NASDAQ:ALIM) will post earnings per share (EPS) of ($0.04) for the current quarter, according to Zacks. Two analysts have made estimates for Alimera Sciences’ earnings, with estimates ranging from ($0.05) to ($0.03). Alimera Sciences posted earnings per share of ($0.10) in the same quarter last year, which would suggest a positive year-over-year growth rate of 60%. The firm is scheduled to issue its next earnings results on Wednesday, February 27th.
On average, analysts expect that Alimera Sciences will report full-year earnings of ($0.22) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($0.14) per share, with EPS estimates ranging from ($0.17) to ($0.11). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Alimera Sciences.
A number of equities analysts recently weighed in on ALIM shares. HC Wainwright set a $3.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Tuesday, November 27th. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. TheStreet upgraded shares of Alimera Sciences from a “d-” rating to a “c-” rating in a report on Tuesday, November 6th. Finally, ValuEngine upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $2.38.
Hedge funds have recently added to or reduced their stakes in the business. B. Riley Wealth Management Inc. bought a new position in Alimera Sciences during the third quarter worth $81,000. Royce & Associates LP bought a new position in Alimera Sciences during the third quarter worth $195,000. BlackRock Inc. boosted its position in Alimera Sciences by 28.5% during the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 60,327 shares during the period. B. Riley Financial Inc. bought a new position in Alimera Sciences during the third quarter worth $447,000. Finally, Renaissance Technologies LLC boosted its position in Alimera Sciences by 20.8% during the second quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 99,000 shares during the period. 52.30% of the stock is owned by hedge funds and other institutional investors.
ALIM traded up $0.02 during trading on Friday, reaching $1.00. 44,766 shares of the stock were exchanged, compared to its average volume of 85,795. The company has a market cap of $68.68 million, a price-to-earnings ratio of -3.45 and a beta of 2.17. Alimera Sciences has a twelve month low of $0.72 and a twelve month high of $1.34.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.